Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 1/20 | 0.53 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.42 |
| ▸ | RORC | P51449 | 5/20 | 0.38 |
| ▸ | CKS1B | P61024 | 1/20 | 0.37 |
| ▸ | SKP1 | P63208 | 1/20 | 0.37 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.37 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.36 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | NAPEPLD | Q6IQ20 | 1/20 | 0.36 |
| ▸ | MMP12 | P39900 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16304060 | 1.00 | PTGER4 (0.53) | PTGER4MDM2RORCCKS1BSKP1 | |
| SCHEMBL17684635 | 0.92 | PTGER4 (0.45) | PTGER4MDM2RORCCKS1BSKP1 | |
| SCHEMBL17684637 | 0.92 | PTGER4 (0.45) | PTGER4MDM2RORCCKS1BSKP1 | |
| SCHEMBL16304061 | 0.92 | PTGER4 (0.51) | PTGER4MDM2RORCCKS1BSKP1 | |
| SCHEMBL20113515 | 0.92 | PTGER4 (0.51) | PTGER4MDM2RORCCKS1BSKP1 | |
| SCHEMBL17684492 | 0.91 | PTGER4 (0.54) | PTGER4MDM2RORCCKS1BSKP1 | |
| SCHEMBL16305068 | 0.91 | PTGER4 (0.54) | PTGER4MDM2RORCCKS1BSKP1 | |
| SCHEMBL16304872 | 0.91 | AGTR2 (0.42) | PTGER4MDM2RORCCKS1BSKP1 | |
| SCHEMBL17684430 | 0.86 | PTGER4 (0.55) | PTGER4MDM2RORCCKS1BSKP1 | |
| SCHEMBL17684429 | 0.86 | PTGER4 (0.55) | PTGER4MDM2RORCCKS1BSKP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3009426-B1 | 4-ALKYNYL IMIDAZOLE DERIVATIVE AND MEDICINE COMPRISING SAME AS ACTIVE INGREDIENT | KAKEN PHARMA CO LTD (JP) | 2018-05-02 | — | — | EP | disclosed |
| US-9855257-B2 | 4-alkynyl imidazole derivative and medicine comprising same as active ingredient | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2018-01-02 | — | — | US | disclosed |
| US-20170128431-A1 | 4-ALKYNYL IMIDAZOLE DERIVATIVE AND MEDICINE COMPRISING SAME AS ACTIVE INGREDIENT | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2017-05-11 | — | — | US | disclosed |
| US-9593081-B2 | 4-alkynyl imidazole derivative and medicine comprising same as active ingredient | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2017-03-14 | — | — | US | disclosed |
| US-20160130232-A1 | 4-ALKYNYL IMIDAZOLE DERIVATIVE AND MEDICINE COMPRISING SAME AS ACTIVE INGREDIENT | KAKEN PHARMACEUTICAL CO., LTD. (JP) | 2016-05-12 | — | — | US | disclosed |
| EP-3009426-A1 | 4-ALKYNYL IMIDAZOLE DERIVATIVE AND MEDICINE COMPRISING SAME AS ACTIVE INGREDIENT | Kaken Pharmaceutical Co., Ltd. (JP) | 2016-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160130232-A1 | 4-ALKYNYL IMIDAZOLE DERIVATIVE AND MEDICINE COMPRISING SAME AS ACTIVE INGREDIENT | PTGER4, IL4, PTGER1 | PTGER4 1/4885MDM2 4017/4885RORC 43/4885 |
| US-20170128431-A1 | 4-ALKYNYL IMIDAZOLE DERIVATIVE AND MEDICINE COMPRISING SAME AS ACTIVE INGREDIENT | PTGER4, IL4, PTGER1 | PTGER4 1/4885MDM2 4001/4885RORC 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.